-
1 month ago | 
blackhealthmatters.com | Bristol Myers Squibb |Keyaira Boone
Presented By Bristol Myers SquibbDr. Amany Keruakous, MD, shared vital information about multiple myeloma with the audience at the Black Health Matters 2025 Health Summit & Expo. Multiple myeloma disproportionately impacts the Black community in major ways.
-
Jan 15, 2025 | 
biospace.com | Bristol Myers Squibb
The 2024 venture capital story was defined by megarounds, established leadership teams and a rise in overall capital over 2023. Investment in biopharma surpassed 2023’s figure, with $26 billion raised in 2024 compared to $23.3 billion the year prior, despite there being fewer funding rounds—416 versus 462. However, that money was not spread evenly across the industry as demonstrated by some massive raises for a few high-profile biotechs with known leadership teams.
-
Nov 22, 2024 | 
consejosdetufarmaceutico.com | Bristol Myers Squibb
Vencer al cáncer a partir de las propias células del paciente. Ese es el principio que alienta la terapia con células CAR-T, un nuevo abordaje en el tratamiento de algunos tumores de la sangre como el mieloma múltiple. Viene a ser algo así como “instruir a las propias células”, que son modificadas para que ataquen de manera específica a las células malignas, convirtiéndose en células “devora tumores”.
-
Nov 19, 2024 | 
markets.financialcontent.com | Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research programs at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California.
-
Nov 15, 2024 | 
markets.financialcontent.com | Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab)for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
-
Nov 15, 2024 | 
markets.financialcontent.com | Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), as a treatment for adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) and for the treatment of adult and pediatric patients 12 years of age and older with advanced solid tumors expressing a NTRK gene fusion, and who have...
-
Nov 11, 2024 | 
markets.financialcontent.com | Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place November 16-18, 2024, in Chicago, Illinois.
-
Nov 5, 2024 | 
markets.financialcontent.com | Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024. Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer and Head of Development, and Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer, will take part in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference. They will answer questions about the company beginning at 10:00 a.m. ET on November 11, 2024.
-
Oct 31, 2024 | 
markets.financialcontent.com | Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) today announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY™ (xanomeline and trospium chloride) in adults with schizophrenia over 52 weeks of treatment. Data were presented at the 2024 Psych Congress, taking place from October 29 – November 2, 2024 in Boston, MA.
-
Oct 31, 2024 | 
markets.financialcontent.com | Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024. "We made important strides in the third quarter with the landmark U.S. approval of Cobenfy in schizophrenia, continued sales momentum, strong cash flow generation and key pipeline achievements," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb.
